Early detection and quick response are key to defense against anthrax attackJuly 27, 2009Delays could overwhelm hospitals, according to new study by Weill Cornell Medical School Public Health researchers NEW YORK -- A large attack on a major metropolitan area with airborne anthrax could affect more than a million people, necessitating their treatment with powerful antibiotics. A new study finds that in order for a response to be effective, quick detection and treatment are essential, and any delay beyond three days would overwhelm hospitals with critically ill people. The results of a computer simulation study appear in the July/August edition of the journal Medical Decision Making -- one of two studies by Dr. Nathaniel Hupert of Weill Cornell Medical College in the issue. The study can be found at http://mdm.sagepub.com/cgi/rapidpdf/0272989X09341389v1 "No matter how well-organized and prolonged a treatment program is, it must be quickly implemented. In fact, our analysis shows that time-to-treatment is roughly twice as important as the duration of the distribution program," says lead author Dr. Nathaniel Hupert, associate professor of public health and medicine at Weill Cornell Medical College. "Crucial to rapidly implementing a treatment program is early detection, including thorough use of advanced biosurveillance technologies and live, person-to-person communication," continues Dr. Hupert, who is also director of the new Preparedness Modeling Unit at the U.S. Centers for Disease Control and Prevention (CDC). "But most important of all are multilateral diplomatic efforts to prevent bioterrorist attacks from ever happening." The study predicts that a campaign initiated two days after exposure would protect as many as 87 percent of exposed individuals from illness -- a rate considered successful by the CDC. Each additional day needed to complete the campaign would result in an average of up to 2.9 percent more hospitalizations in the exposed population. And each extra day of delay to the start of the program beyond two days would result in up to 6.5 percent more hospitalizations. Anthrax attack scenarios typically involve the release of one kilogram of weaponized anthrax from a small airplane flying over a major city. The invisible powder could be inhaled by thousands or hundreds of thousands, who would start becoming sick anywhere from 24 hours to a week or more after the attack. With appropriate and timely administration of an antibiotic treatment program, exposed individuals would be spared from developing inhalational anthrax infection. New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College |
|||||||||||||||||||||
| Related Anthrax Current Events and Anthrax News Articles Milestone biodefense publication by Elsevier journal Vaccine Last week during the 'Vaccines for Biothreats and Emerging and Neglected Diseases Symposium' in Galveston TX, USA, the Elsevier journal Vaccine released a supplement dedicated to vaccines for biodefense. Cigarettes Harbor Many Bacteria Harmful to Human Health Cigarettes are "widely contaminated" with bacteria, including some known to cause disease in people, concludes a new international study conducted by a University of Maryland environmental health researcher and microbial ecologists at the Ecole Centrale de Lyon in France. New explanation for nature's hardiest life form Got food poisoning? The cause might be bacterial spores, en extremely hardy survival form of bacteria, a nightmare for health care and the food industry and an enigma for scientists. Better immune defense against anthrax Scientists discover a gene in anthrax-causing bacteria may help defend against this form of bio-warfare. Argonne researchers develop method that aims to stabilize antibodies Researchers at the U.S. Department of Energy's Argonne National Laboratory have developed a systematic method to improve the stability of antibodies. Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication by the New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal antibody drug raxibacumab. One secret to how TB sticks with you Mycobacterium tuberculosis is arguably the world's most successful infectious agent because it knows how to avoid elimination by slowing its own growth to a crawl. Unexpected discovery can open a new chapter in the fight against tuberculosis A close relative of the microorganism that causes tuberculosis in humans has been found to form spores. Genetic switch potential key to new class of antibiotics Researchers have determined the structure of a key genetic mechanism at work in bacteria, including some that are deadly to humans, in an important step toward the design of a new class of antibiotics. UI chemists' DNA biosynthesis discovery could lead to better antibiotics Combating several human pathogens, including some biological warfare agents, may one day become a bit easier thanks to research reported by a University of Iowa chemist and his colleagues in the April 16 issue of the journal Nature. More Anthrax Current Events and Anthrax News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||